TEE
VKTX icon

Tibra Equities Europe’s Viking Therapeutics VKTX Stock Holding History

Tibra Equities Europe’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-87,791
Closed -$384K – 202
2018
Q1 		$384K Buy
+87,791
New +$486K 0.07% 152

Other funds holding VKTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tibra Equities Europe's VKTX Position: Q2 2018 in Review

Tibra Equities Europe sold out of Viking Therapeutics (VKTX) in Q2 2018, closing a stake of 87,791 shares — an estimated $384K sold.

Tibra Equities Europe first reported a position in VKTX in Q1 2018 and held it in 1 quarter. The position peaked at $384K in Q1 2018. 116 funds tracked by Wall St. Rank hold VKTX as of Q2 2018.

  • Tibra Equities Europe reported no remaining Viking Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Tibra Equities Europe sold 87,791 Viking Therapeutics shares in Q2 2018, an estimated $384K.
  • Tibra Equities Europe first reported a position in Viking Therapeutics in Q1 2018 and held it in 1 quarter.
  • Tibra Equities Europe's Viking Therapeutics position peaked at $384K in Q1 2018.
  • 116 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2018.

Based on Tibra Equities Europe's 13F filing for Q2 2018, filed 10 Aug 2018.